35 Recruiting Advanced Lymphoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Top Recruiting Advanced Lymphoma Studies
Studying TAK-243 in Patients With Advanced Cancer
📍 National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
View Study & Checklist ➔Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔